CD47 and neoplasm: The anti-tumor activity of the anti-CD47 blocking antibody, Hu-5F9, was assessed (compared to control and to Olaparib) in a PDX model of chemotherapy resistant, PARP inhibitor resistant high grade serous ovarian cancer.